The course of hepatitis C viraemia in transfusion recipients prior to availability of antiviral therapy

Journal of Viral Hepatitis

Volumn 15, Issue 2, 2008, Pages 120-128

  Mosley, J W ^a,h   Operskalski, E A ^a   Tobler, L H ^b   Buskell, Z J ^c   Andrews, W W ^d   Phelps, B ^d   Dockter, J ^e   Giachetti, C ^e   Seeff, L B ^c,f   Busch, M P ^b,g  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

^e Gen Probe Incorporated   (United States)

^f NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h NONE   (United States)

Author keywords

Alanine aminotransferase; Blood transfusion; Hepatitis C infection; Prospective studies; Transcription mediated amplification; Viral RNA

Indexed keywords

ALANINE AMINOTRANSFERASE; VIRUS RNA;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; ASSAY; BLOOD TRANSFUSION; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MONITORING; POSTTRANSFUSION HEPATITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; SERUM; SEX RATIO; TRANSCRIPTION MEDIATED AMPLIFICATION ASSAY; TREATMENT PLANNING; VETERANS ADMINISTRATION STUDY; VIREMIA; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; BLOOD DONORS; BLOOD TRANSFUSION; HEPACIVIRUS; HEPATITIS C; HUMANS; PROSPECTIVE STUDIES; RNA, VIRAL; VIRAL LOAD; VIREMIA;

EID: 37649018343     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2007.00900.x     Document Type: Article

References (42)

1. Thomas DL, Seeff LB. Natural history of hepatitis C. Clin Liver Dis 2005 9 : 283 298.
2. Alberti A, Benvegnù L. Management of hepatitis C. J Hepatol 2003 38 : S104 S118.
3. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 1171.
4. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. New Engl J Med 2001 345 : 1452 1457.
5. Gerlach JT, Diepolder HM, Zachoval R et al. Acute hepatitis C: High rate of both spontaneous and treatment-induced viral clearance. Gastroenterology 2003 125 : 80 88.
6. Nomura H, Sou S, Tanimoto H et al. Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology 2004 39 : 1213 1209.
7. Kamal SM, Simail A, Graham CS et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C virus-specific T cell response kinetics. Hepatology 2004 39 : 1721 1731.
8. Wiegand J, Buggisch P, Boecher W, et al. Early monotherapy with pegylated interferon alpha-2g for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology 2006 43 : 250 256.
9. Russo MW, Fried MW. Side effects of therapy for chronic hepatitis. Gastroenterology 2003 124 : 1711 1719.
10. Zekry A, Patel K, McHutchison JG. Treatment of acute hepatitis C infection: more pieces of the puzzle. J Hepatol 2005 42 : 293 296.
11. Craxi A, Licata A. Acute hepatitis C: in search of the optimal approach to cure. Hepatology 2006 43 : 221 224.
12. Busch MP. Closing the windows on viral transmission by blood transfusion. In : Stramer SL, ed. Blood Safety in the New Millennium. Bethesda, MD : American Association of Blood Banks, 2001 : 33 54.
13. Mosley JW, Operskalski EA, Tobler LH et al. Viral and host factors in early hepatitis C virus infection. Hepatology 2005 42 : 86 92.
14. Seeff LB, Hollinger FB, Alter HJ et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung and Blood Institute collaborative study. Hepatology 2001 33 : 455 563.
15. Hollinger FB, Mosley JW, Szmuness W et al. Non-A, non-B hepatitis following blood transfusion: risk factors associated with donor characteristics. In : Szmuness W, Alter HJ, Maynard JE, eds. Viral Hepatitis; 1981 International Symposium. Philadelphia : Franklin Institute Press, 1982 : 361 376.
16. Mosley JW, Goodwin RG. Stability of serum glutamic pyruvic transaminase activity on storage. Am J Clin Pathol 1965 44 : 591.
17. Operskalski EA, Mosley JW, Tobler LH et al. HCV viral load in anti-HCV-reactive donors and infectivity for their recipients. Transfusion 2003 43 : 1433 1441.
18. Dockter J, Schneider W, Cox D, Millar C, McDonough S, Giachetti C. Long term stability of HIV-1 and HCV specimens collected in different anticoagulants and stored at -20°C or -70°C. Transfusion 2003 41 (Suppl 121A 122A.
19. Seeff LB, Miller RN, Rabkin CS et al. 45-Year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med 2000 132 : 105 111.
20. Giachetti C, Linnen J, Kolk DP et al. Highly sensitive multiplex assay for detection of HIV-1 and HCV RNA. J Clin Microbiol 2002 40 : 1761 1766.
21. Desombere I, Van Vlierberghe H, Couvent S, Clinckspoor F, Leroux-Roels G. Comparison of quantitative (COBAS AMPLICOR HCV 2.0 versus VERSANT HCV RNA) and quantitative (COBAS AMPLICOR HCV Monitor 2.0 versus VERSANT HCV RNA 3.0) assays for hepatitis C virus(HCV) and quantitation: impact on diagnosis and treatment of HCV infections. J Clin Microbiol 2005 43 : 2590 2597.
22. Gerotto M, Dal Pero F, Bortoletto G et al. Hepatitis C minimal residual viremia (MRV) detected by TMA at the end of Peg-IFN plus ribavirin therapy predicts post-treatment relapse. J Hepatol 2006 44 : 83 87.
23. Macedo Oliveira A, White KL, Beecham BD et al. Sensitivity of second-generation enzyme immunoassay for detection of hepatitis C virus infection among oncology patients. J Clin Virol 2006 35 : 1 25.
24. Mathurin P, Moussalli J, Cadranel J-F et al. Show progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity. Hepatology 1998 27 : 868 872.
25. Hirsch KR, Wright TL. The dilemma of disease progression in hepatitis C patients with normal serum aminotransferase levels. Amer J Med 2000 109 : 66 67.
26. Tibbs CJ. Methods of transmission of hepatitis C. J Viral Hepatitis 1995 2 : 113 119.
27. Thimme R, Oldach D, Chang K-M, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C infection. J Exp Med 2001 194 : 1395 1406.
28. Massari M, Petrosillo N, Ippolito G et al. Transmission of hepatitis C virus in a gynecological surgery setting. J Clin Microbiol 2001 39 : 2860 2863.
29. Widell A, Christensson B, Liebe T et al. Epidemiologic and molecular investigation of outbreaks of hepatitis C virus infection on a pediatric oncology service. Ann Intern Med 1999 130 : 130 134.
30. Macedo de Oliveira A, White KL, Leschinsky DP et al. An outbreak of hepatitis C virus infections among outpatients at a hematology/oncology clinic. Ann Intern Med 2005 142 : 898 902.
31. Larghi A, Zuin M, Crosignani A et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology 2002 36 : 993 1000.
32. Thorpe LE, Ouellet LJ, Hershow R et al. Risk of hepatitis C virus infection among young adult injection drugs users who share injection equipment. Am J Epidemiol 2002 155 : 645 653.
33. Thomas DL, Zenilman AM, Alter HJ et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J Infect Diseases 1995 171 : 768 775.
34. Spada E, Mele A, Berton A et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut 2004 53 : 1673 1681.
35. Fang CT, Tobler LH, Haesche C, Busch MP, Phelps B, Leparc G. Fluctuations of HCV viral load before seroconversion in a healthy volunteer blood donor. Transfusion 2003 43 : 541 544.
36. Beld M, Penning M, McMorrow M, Gorgels J, van den Hoek A, Goudsmit J. Different hepatitis C virus (HCV) RNA load profiles following seroconversion among injecting drug users without correlation with HCV genotype and serum alanine aminotransferase. J Clin Microbiol 1998 36 : 872 877.
37. Santantonio T, Sinisi E, Guastadisegni A et al. Natural course of acute hepatitis C: a long-term prospective study. Dig Liv Dis 2003 35 : 104 113.
38. Missale G, Bertoni R, Lamonaca V et al. Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response. J Clin Invest 1996 98 : 706 714.
39. + T-cell response in acute hepatitis C. Gastroenterology 1999 117 : 933 941.
40. Thimme R, Bukh J, Spangenberg HC et al. Viral and immunological determinants of hepatitis C virus clearance, persistence, and disease. Proc Natl Acad Sci U S A 2002 99 : 15661 15668.
41. Barrera JM, Bruguera M, Ercilla MG et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995 21 : 639 644.
42. Prince AM, Pawlotsky J-M, Soulier A et al. Hepatitis C virus replication kinetics in chimpanzees with self-limited and chronic infections. J Viral Hepatitis 2004 11 : 236 242.